Is MiMedx Group, Inc. (MDXG) Overvalued?
We dive into why MiMedx Group, Inc. (MDXG) could be considered overvalued on 2026-08-07, based on AAII’s Value Score and Grade.Michael Rose
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
MiMedx Group, Inc. develops and distributes placental tissue allografts for various sectors of healthcare. The company processes the human placental tissues membrane, and umbilical cord and the placental disc utilizing its patented and proprietary PURION process to produce allografts that retains the tissue’s inherent biological properties and regulatory proteins, including cytokines, chemokines, and growth factors. Its patented and proprietary processing method employs aseptic processing techniques in addition to terminal sterilization. The company’s wound care products include EPIFIX, EPICORD, EPIXPRESS, CHORIOFIX, EMERGE, CELERA, REGENKIT WOUND GEL, and EPIEFFECT sheets for use as protective barriers that enables a healthcare provider to select an appropriate size graft based on the size of the wound to reduce product waste. Its surgical and other product offerings consist of AMNIOFIX, AMNIOBURN, AMNIOCORD, AXIOFILL, HELIOGEN, and AMNIOEFFECT for applications in a variety of applications and surgical settings, including lower extremity repair, plastic surgery, vascular surgery, and various orthopedic repairs and reconstructions. The company’s products are used in the areas of wound care, burn, and surgical fields in healthcare. It sells its products through direct sales force and independent sales agents, as well as to individual customers and independent distributors in the United States. The company has a strategic alliance with Vaporox, Inc. for the promotion of their wound care offerings. The company was founded in 2006 and is headquartered in Marietta, Georgia.
Commentary & Analysis
Why MiMedx Group, Inc.’s (MDXG) Stock Is Up 6.05%
As of Monday, August 03, MiMedx Group, Inc.’s MDXG share price has surged by 6.05%, which has investors questioning if this is right time to sell.Cynthia McLaughlin
Why MiMedx Group, Inc.’s (MDXG) Stock Is Down 5.39%
As of Friday, July 31, MiMedx Group, Inc.’s MDXG share price has dipped by 5.39%, which has investors questioning if this is right time to buy.Cynthia McLaughlin
What You Need to Know About MiMedx Group, Inc.'s Q3 Earnings
MiMedx Group, Inc.'s fiscal Q3 earnings report was released on Wednesday, July 29. Let's dive in to see if (MDXG) missed or beat analyst's expectations.Michael Rose
Why MiMedx Group, Inc.’s (MDXG) Stock Is Up 6.10%
As of Friday, May 01, MiMedx Group, Inc.’s MDXG share price has surged by 6.10%, which has investors questioning if this is right time to sell.Michael Rose
Financial Summary
| Share Statistics | MDXG | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $631.1 | $292.6 | 39% |
|
| Shares Out (Mil) | 147.8 | 54.4 | 70% |
|
| Institutional Ownership | 96.8% | 93.2% | 71% |
|
| Float (Mil) | 114.8 | 40.2 | 64% |
|
| Beta | na | 0.94 | na |
|
| Avg Daily Volume (000s) | 1,076 | 544 | 72% |
|
| Price Change (52-week) |
(39.6%) | 59.7% | 18% |
|
| Growth | MDXG | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | 11.0% | 13.6% | 62% |
|
| Net Income (5yr) | 24.5% | (10.1%) | 79% |
|
| EPS (5yr) | 19.3% | 16.0% | 67 |
|
| Dividends (5yr) | 0.0% | 0.0% | 0% |
|
| Cash Flow (5yr) | 10.9% | (15.6%) | 70% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 3 | 3 | 3 | |
| Current EPS | $0.007 | ($0.053) | $0.173 | |
| Month Ago EPS | ($0.003) | ($0.070) | $0.143 | |
| # Rev Up | 0 | 1 | 1 | |
| # Rev Down | 1 | 0 | 0 | |
| Three Months Ago EPS | ($0.003) | ($0.075) | $0.123 | |
| Year/Year Chg | (107.0%) | (116.6%) | (18.8%) | |
| Financials | MDXG | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $355 | $37 | 37% |
|
| Net Income (TTM) (Mil) | $6 | ($43) | 43% |
|
| EPS (TTM) | $0.042 | ($1.400) | 41% |
|
| Operating Cash Flow (TTM) (Mil) | $46 | ($31) | 46% |
|
| Net Cash Flow (TTM) (Mil) | $17 | $2 | 61% |
|
| Long-Term Debt (Q1) (Mil) | $16 | $4 | 31% |
|
| Enterprise Value (Q1) (Mil) | na | $164 | na |
|
| Valuation | MDXG | Industry Median |
Percentile (All Stocks) |
|
| P/B | 2.93 | 2.83 | 63% |
|
| P/E | 103.1 | 19.6 | 93% |
|
| Dividend Yield | 0.0% | 0.0% | 0% |
|
| PEG (5yr hist) | 5.3 | 1.0 | 88% |
|
| Ratios | MDXG | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | 78.8% | 64.2% | 88% |
|
| Net Margin | 1.8% | (75.9%) | 37% |
|
| ROA | 2.2% | (47.5%) | 57% |
|
| ROE | 2.9% | (55.0%) | 40% |
|
| Liabilities to Assets | 23.1% | 29.6% | 16% |
|
| F-Score | 5 | 3 | 50% |
|
MiMedx Group, Inc. did not pass any screens on 8/21/2026.
